Clinical trial
A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)
NCT06944145 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 3, 2025
- Completion date
- August 31, 2030
- Enrollment
- 242 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bph (benign prostatic hyperplasia), lower urinary track symptoms